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Abstract
As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced 
thyroid abnormalities will increase. In this study we compared rates of therapy-induced 
hypothyroidism in 329 patients with DLBCL treated with conventional chemotherapy (DLBCL-c) 
or conventional chemotherapy plus lenalidomide (DLBCL-len). We measured serum levels of 
tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin-6 (IL-6), 
interleukin-12 (IL-12), and interleukin-15 (IL-15) before and after treatment. We found a 
significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs 





Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin 
Lymphoma (NHL). Up to one-third of patients with DLBCL treated with standard 
chemotherapy exhibit refractory disease or suffer disease relapse. The use of lenalidomide 
monotherapy and lenalidomide in combination with rituximab is being investigated in phase 
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II and phase III clinical trials in patients with refractory or relapsed DLBCL[1–5]. Our 
institution has conducted a randomized phase II trial of lenalidomide with or without 
rituximab to treat patients with high-intermediate or high-risk DLBCL (NCT #00765245).
Rituximab is a chimeric monoclonal antibody directed against the cluster of differentiation 
20 (CD20) antigen on B lymphocytes, and it has not been associated with clinical or 
subclinical hypothyroidism. Lenalidomide is a thalidomide-analogue immunomodulatory 
drug (IMiD). IMiDs exert their antineoplastic effect through a multitude of mechanisms 
affecting not only malignant cells but also immune effector and stromal cells. IMiDs 
promote T cell proliferation, induce endogenous cytokine release, inhibit angiogenesis, and 
increase natural killer (NK) cell numbers and function[6–9].
In contrast to thalidomide, lenalidomide is more potent and has fewer associated adverse 
reactions. While thalidomide use is associated with clinical or subclinical hypothyroidism in 
up to 20% of patients[6,10], the association between lenalidomide and hypothyroidism is 
less commonly observed and is thought to occur in 5–10% of patients[6,11]. In the largest 
retrospective review to date (n=170), ten patients (6%) with multiple myeloma (MM) 
developed thyroid abnormalities attributable to lenalidomide[11]. The mechanism of 
lenalidomide-induced hypothyroidism is unknown. Proposed mechanisms include initiation 
of autoimmune thyroid destruction through pro-inflammatory cytokine deregulation, 
inhibition of iodine uptake[12], direct thyroid cell injury, and decreased thyroid secretory 
capacity[6,10,13].
In order to determine the role of inflammatory cytokines in lenalidomide-induced 
hypothyroidism, we measured pre- and post-treatment levels of TNF-α, IFN-γ, IL-6, IL-12, 
and IL-15 in patients with DLBCL treated with lenalidomide with or without rituximab. We 
also compared the rates of hypothyroidism between patients treated with standard 
chemotherapy alone for DLBCL and those who received lenalidomide in addition to 
standard therapy.
2. Materials and Methods
2.1 Patient selection
Three hundred and twenty nine consecutive patients older than 18 years diagnosed with 
DLBCL diagnosed between 2000 and 2013 who received treatment at Vanderbilt University 
Medical Center were included in our study. No patients were excluded for any reason. 
Corresponding medical records were reviewed and data detailing patient age, gender, 
Eastern Cooperative Oncology Group (ECOG) performance status, Ann Arbor stage, 
extranodal disease involvement, International Prognostic Index (IPI), therapy received, and 
the development of hypothyroidism was extracted. The Institutional Review Board of 
Vanderbilt University Medical Center approved this retrospective chart review and 
corresponding serum analysis.
2.2 Lenalidomide schedule and dosing
The doses of lenalidomide varied between 10 mg and 25 mg administered on a 21 day 
schedule for 12 cycles. For patients receiving combination therapy, rituximab (375 mg/m2) 
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was administered on day eight of odd numbered cycles. Rituximab was administered as part 
of a prospective study as maintenance therapy following chemotherapy for high-risk 
DLBCL (clinical trials.gov # NCT00765245). Three patients who received lenalidomide off 
study for disease relapse were also included in this analysis.
2.3 Hypothyroidism diagnosis, grading, and treatment
The primary outcome of the study was the development of hypothyroidism. Hypothyroidism 
was diagnosed by elevated thyroid stimulating hormone (TSH) level accompanied by 
decreased thyroxine (T4) level. Grading of hypothyroidism was symptom-based as defined 
by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 (Table 1). Abnormal thyroid function tests were defined as TSH above 
or below the normal reference range (0.3–5.0 mU/ml) and correlated with Free T4 levels. 
Patients who were on the clinical trial had TSH checked routinely every four months per 
protocol. All patients who developed hypothyroidism were treated with levothyroxine, and 
all patients achieved normalization of their thyroid function tests within 4.0 months ± 1.6 
months. Dose adjustments in lenalidomide occurred for grade 3 non-hematological toxicity, 
including hypothyroidism.
2.4 Cytokine analysis
Peripheral blood samples were collected in EDTA tubes from 31 patients on day 0, prior to 
the initiation of lenalidomide, and day 28, following completion of 21 days of therapy with 
lenalidomide as described above. Mononuclear cells and red cells were isolated from serum 
and stored at −80. Analysis was performed at the completion of the study. Serum levels of 
TNF- α, IFN-γ, IL-6, IL-12, and IL-15 were analyzed in duplicate with a high sensitivity 
human cytokine kit using luminex technology. Cytokine levels were detectable in 27 
patients, and these patients were included in the statistical analysis.
3. Statistical analysis
Non-parametric analysis was performed. Baseline patient characteristics and disease-related 
variables were described with median and range for continuous variables and percent of total 
for categorical variables. Student’s t test (for paired samples) was used for the statistical 
analysis. The Mann-Whitney U rank sum test was used to compare continuous variables. For 
ratio comparisons, the X2-test or Fisher’s exact test was used. All statistical tests were two-
sided, and an α of 0.05 was used to determine statistical significance. Statistical analyses 
were performed using SPSS software (v.21) (IBM-SPSS, Chicago, IL, USA).
4. Results
4.1 Patient characteristics
Patient and disease-related characteristics are presented in Table 2.
A total of 329 patients with DLBCL were included in this study. Of these, 31 patients were 
treated with lenalidomide (n=15) or lenalidomide and rituximab (n=16). The median age of 
all patients with DLBCL was 60 years (range 17 years - 97 years), and the median age of the 
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patients who received lenalidomide as part of their treatment was 56 years (range 29 years – 
85 years).
4.2 Treatment regimens and development of hypothyroidism
Of the 329 patients with DLBCL, 298 (90.6%) patients were treated with conventional 
chemotherapy (c) with or without stem cell transplantation (DLBCL-c). Thirty one (9.4%) 
patients received conventional chemotherapy and lenalidomide as either maintenance 
therapy or salvage treatment (DLBCL-len). Complete data was missing on a total of 34 
patients in DLBCL-c, but these patients were included since they had documentation of 
thyroid function testing. Data was complete on all patients in the DLBCL-len arm. Fourteen 
patients (4.7%) received radiation therapy to the neck or mediastinum. None of the patients 
receiving lenalidomide had radiation as part of their treatment regimen. In the DLBCL-c arm 
30 patients (10%) had pre-existing thyroid abnormalities, while in the DLBCL-len arm two 
patients (6.4%) had pre-existing thyroid dysfunction. Of these two patients, one had 
hypothyroidism and the other had hyperthyroidism. In the DLBCL-c arm, four patients 
(1.3%) were diagnosed with hypothyroidism after starting conventional therapy, while in the 
DLBCL-len arm eight patients (25.8%) were diagnosed with hypothyroidism after initiating 
lenalidomide (p<0.0001). The median onset of thyroid abnormalities after initiation of 
lenalidomide was 5.2 months. All patients in the DLBCL-c arm had grade 2 hypothyroidism 
by CTCAE criteria (Table 1). Five patients in the DLBCL-len arm had grade 2 and three had 
grade 3 hypothyroidism. Two patients who developed thyroid abnormalities in the DLBCL-c 
group had received prior radiation to the mediastinum.
4.3 Cytokine abnormalities in patients treated with lenalidomide
Serum levels of TNF- α, IFN-γ, IL-6, IL-12, and IL-15 were measured at pre-specified time 
intervals. There was a non-significant increase in the levels of these cytokines in the twenty-
seven patient cohort receiving lenalidomide. There was no quantitative difference in 
cytokine levels when comparing patients who received lenalidomide with or without 
rituximab (Figure 1a–1c). At baseline in all twenty-seven patients treated with lenalidomide, 
the mean serum levels of TNF- α, IFN-γ, IL-6, IL-12, and IL-15 were 14.1pg/ml, 
5.82pg/ml, 4.19pg/ml, 3.58pg/ml, and 2.89pg/ml, respectively. After 21 days of treatment 
with lenalidomide, the mean levels of TNF- α, IFN-γ, IL-6, IL-12, and IL-15 were 
17.6pg/ml, 7.73pg/ml, 6.89pg/ml, 4.61pg/ml, and 3.28 pg/ml, respectively. None of these 
differences reached statistical significance (P= 0.09, 0.56, 0.13, 0.54 and 0.65 respectively).
5. Discussion
Serum cytokine levels pre and post lenalidomide therapy in patients who developed new or 
worsening thyroid function test abnormalities were available in all ten patients. Eight 
patients developed new onset hypothyroidism; two had hypothyroidism at baseline that 
worsened. In the 10 patients who developed new or worsening hypothyroidism after 
treatment with lenalidomide, TNF- α levels significant increased from a mean of 16.2pg/ml 
pre-treatment to 22.9pg/ml post-treatment (p=0.002, 95% CI 4.21–9.03) (Figure 2a–c). In 
these patients who developed worsening hypothyroidism with lenalidomide, there was no 
significant increase in mean IFN-γ, IL-6, IL-12, and IL-15 levels pre- and post-treatment 
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[pre-treatment 13.8pg/ml, 5.65pg/ml, 6.5 pg/ml, 5.25pg/ml and post-treatment 16.7pg/ml, 
9.16pg/ml, 8.25pg/ml, 6.46pg/ml, respectively (p=NS)].
Lenalidomide-induced hypothyroidism is a poorly understood phenomenon that affects 5–
10% of patients receiving this anti-neoplastic agent[6,11,14,15]. In our study cohort of 
DLBCL, we found higher rates of lenalidomide-related hypothyroidism than previously 
reported (1.3% in patients treated with conventional chemotherapy alone versus 25.8% in 
patients treated with conventional chemotherapy and lenalidomide. The addition of 
rituximab did not appear to increase the risk of thyroid abnormalities. A potential 
explanation is that the patients in this study are a unique group with DLBCL, who received 
lenalidomide maintenance with in 8–10 weeks of completing systemic 
immunochemotherapy. Lenalidomide could have potentiated or altered the immune 
reconstitution following administration of chemotherapy that may have been abrogated by a 
longer wash-out period. The mechanism of lenalidomide-induced hypothyroidism is poorly 
understood, and potential mechanisms include inhibition of iodine uptake[12], direct thyroid 
cell injury, decreased thyroid secretory capacity, and initiation of autoimmune thyroid 
destruction through pro-inflammatory cytokine deregulation[6,10,13].
The potential mechanisms of IMiD-induced hypothyroidism have been studied in a rat 
model[13] and through assessments of radioiodine uptake amongst thalidomide-treated 
patients[12]. Despite pro-inflammatory cytokine deregulation being postulated as a 
mechanism of lenalidomide-induced hypothyroidism, pre- and post-treatment serum 
inflammatory cytokine levels following lenalidomide administration have only been 
published in one small case series and have not been assessed in relation to the development 
of hypothyroidism. In a group of six patients with MM and a significant elevation (over 1 
mg/dL increase) in C-reactive protein (CRP) after lenalidomide treatment, Harada et al. 
found no significant increase in serum tumor necrosis factor alpha (TNF-α), interferon 
gamma (IFN-γ), interleukin-2 (IL-2), or interleukin-6 (IL-6) after therapy[7]
In murine models it has been shown that normal thyroid tissue has TNF-α receptors, and 
that elevated TNF-α levels inhibit thyroid function[16,17]. This finding was further 
confirmed by Diez et al. when they evaluated serum TNF α levels in 20 patients with 
hypothyroidism, 20 patients with hyperthyroidism, and 20 healthy control patients. This 
group found that in both patients with hypothyroidism and hyperthyroidism, serum levels of 
TNF-α were significantly elevated compared with control patients[18]. Interestingly, case 
reports have shown both that TNF-α administration for cutaneous T cell lymphoma can 
exacerbate hypothyroidism[19], and that infliximab administration, a monoclonal antibody 
against TNF-α, can reduce thyroid hormone replacement needs in a patient with 
hypothyroidism[20].
While the current study is small and cannot assert causation, the finding of increased serum 
TNFα levels in patients with lenalidomide-induced hypothyroidism has a viable 
pathophysiologic mechanism and has been previously observed in other clinical situations. 
These findings warrant validation studies in larger patient populations. A limitation to our 
study is that the serum cytokine levels were not measured at the time of thyroid function 
abnormalities. Based on the available data, serum TNFα may have been much higher at the 
Iams et al. Page 5













actual time of occurrence of thyroid dysfunction. Another limitation is that patients who 
received lenalidomide on the clinical trial had routine thyroid tests performed per protocol. It 
is however; notable that these patients were symptomatic that may have otherwise prompted 
an evaluation.
6. Conclusions
Lenalidomide-induced hypothyroidism is a poorly-understood adverse event which warrants 
further investigation as its treatment indication expands to treat patients with NHL. We 
found higher rates of hypothyroidism when patients with DLBCL are treated with 
lenalidomide in addition to standard chemotherapy that is likely mediated by TNF-α. We 
recommend close monitoring of thyroid function tests in patients treated with lenalidomide 
for NHL.
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a–c: 1a- serum cytokine levels pre and post lenalidomide based therapy (n=27). 1bserum 
cytokine levels pre and post lenalidomide alone (n=27). 1c-serum cytokine levels pre and 
post lenalidomide with rituximab (n=27).
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a–c: 2a- TNFα levels of all patients pre and post lenalidomide based treatment who 
developed worsening hypothyroidism (n=10), P=0.002 (95% CI 4.21–9.03). 2b-TNFα levels 
pre and post lenalidomide who developed worsening hypothyroidism (n=6), P=0.0053 (95% 
CI 3.07–10.48). 2c- TNFα of patients treated with lenalidomide and rituximab who 
developed worsening hypothyroidism (n=4),
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Table 1
The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v4.0) used 
to grade hypothyroidism
Grade of Hypothyroidism CTCAE Definition
Grade 1 Asymptomatic; clinical or diagnostic observations only; intervention not indicated
Grade 2 Symptomatic; thyroid replacement indicated; limiting instrumental ADL
Grade 3 Severe symptoms; limiting self-care ADL; hospitalization indicated
Grade 4 Life-threatening consequences; urgent intervention indicated
Grade 5 Death
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Table 2
Baseline characteristics.
DLBCL-No Lenalidomide (N = 298) DLBCL- Treated with Lenalidomide 
(N = 31)
Gender
Male 181 (61%) 15 (48%)
Median age (range) 60 (17–97) 56 (29–85)
Pre-existing thyroid abnormalities 30 (10%) 2 (6%)
IPI
0–1 102 (34.2%) -
2 62 (20.8%) 6 (19.3%)
3 61 (20.4%) 18 (58%)
4–5 39 (13%) 7 (22.5%)
N/A 34 (11.4%)
Radiation to mediastinum/neck 14 (5%) 0 (0%)
Thyroid abnormalities diagnosed after lymphoma therapy 4 (1%) 8 (26%)
N/A: not available
Exp Hematol. Author manuscript; available in PMC 2016 August 29.
